P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection

Brown, Ashley; Hézode, Christophe; Zuckerman, Eli; Foster, Graham; Zekry, Amany; Roberts, Stuart K.; Howe, Anita Y.M.; Durkan, C.; Badshah, Cyrus; Zhang, B.; Robertson, Michael; Barr, Eliav; Haber, Barbara

doi:10.1016/s0168-8278(15)30974-0

Cited by 20 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with GT4, SVR12 rates were 90% for participants who received grazoprevir and RBV alone and 100% for those who received grazoprevir with elbasvir and RBV. In patients with GT5, grazoprevir with elbasvir and RBV was more effective (SVR12 100%, n = 4) than grazoprevir and elbasvir alone (SVR12 25%, n = 4) [53].…”

Section: Grazoprevir and Elbasvirmentioning

confidence: 93%

“…With 16 weeks of therapy, SVR12 rates were 97 (103/106) and 92% (97/105) with and without RBV, respectively [52]. The C-SCAPE study evaluated the efficacy and safety of 12 weeks of combinations of grazoprevir, elbasvir and RBV in treatment naïve, noncirrhotic patients with HCV GT2, 4, 5 or 6 infection [53]. Patients received grazoprevir with elbasvir and RBV, grazoprevir and RBV or grazoprevir and elbasvir for 12 weeks.…”

Section: Grazoprevir and Elbasvirmentioning

confidence: 99%

See 1 more Smart Citation

What does the pharmacological future of treating chronic hepatitis C look like?

Heil

Hynicka

Kottilil

et al. 2015

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Development of direct acting antivirals has revolutionized the standard of care for the treatment of hepatitis C virus. New interferon-free regimens provide sustained virologic response rates of >90% in many genotype 1 patients with only 12 weeks of oral therapy. This review will provide a brief overview of current standards of care with a summary of the evidence supporting the recommended combinations of direct acting antivirals. We will discuss the direction of future therapies, with strategies for shorter durations of therapy and new all-oral combinations in the pipeline.

show abstract

Section: Grazoprevir and Elbasvirmentioning

confidence: 93%

Section: Grazoprevir and Elbasvirmentioning

confidence: 99%

What does the pharmacological future of treating chronic hepatitis C look like?

Heil

Hynicka

Kottilil

et al. 2015

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…A small number of HCV GT4‐infected patients were included in the phase 3 studies of elbasvir/grazoprevir, C‐EDGE and C‐SCAPE . Initial observations suggest that ribavirin may confer benefit by maximizing SVR rates.…”

Section: The Role Of Ribavirin In the Interferon‐free Eramentioning

confidence: 99%

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

Feld

Jacobson

Sulkowski

et al. 2016

Liver International

View full text Add to dashboard Cite

Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment‐limiting side effects and its additive toxicity with interferon, the search for interferon‐ and ribavirin‐free regimens has been underway. The recent approvals of all‐oral direct acting antivirals (DAAs) have revolutionized the HCV therapeutic landscape, and initially it was expected that the role of ribavirin with DAA regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co‐administered with all‐oral DAA combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all‐oral DAA HCV treatment and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups.

show abstract

“…The possibility to treat patients suffering from end-stage renal disease with a Rbv-free regimen resulted in good safety profile with less than 4 % of patients developing grade 3 anemia. As Grazoprevir and Elbasvir have been demonstrated to be active also on HCV-2 in a previous phase II trial [39], translating results from endstage renal disease HCV-1 patients to other genotypes could be further investigated.…”

Section: Treatment Of Hcv-2 Special Populationsmentioning

confidence: 99%

Genotype 2 Patients: What is the Optimum Therapy so Far?

Degasperi

Aghemo

2015

Curr Hepatology Rep

View full text Add to dashboard Cite

Since optimization studies with Peginterferon (PegIFN) and Ribavirin (Rbv), antiviral treatment of hepatitis C virus (HCV) genotype 2 patients consisted in a 24-week course of dual therapy, resulting in 80-85 % sustained virological response (SVR) rates. PegIFN/Rbv combination was effective in most patients; however, it was burdened by side effects and was suboptimal in difficult-to-treat subgroups, like advanced fibrosis stages. Despite the attempts of treatment individualization according to baseline and on-treatment predictors to increase efficacy and tolerability, many patients had no access to treatment due to comorbidities contraindicating PegIFN administration. In this scenario, the development of new drugs directly targeting HCV replication cycle opened the way to IFN-free combination regimens that could not only increase efficacy but also, most of all, reduce side effects and expand treatment access. This review is focused on new treatment options in HCV-2 patients, from phase III studies to real-life data.

show abstract

P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection

Cited by 20 publications

References 0 publications

What does the pharmacological future of treating chronic hepatitis C look like?

What does the pharmacological future of treating chronic hepatitis C look like?

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

Genotype 2 Patients: What is the Optimum Therapy so Far?

Contact Info

Product

Resources

About